EP1420747A4 - Ansamycine benzoquinone - Google Patents

Ansamycine benzoquinone

Info

Publication number
EP1420747A4
EP1420747A4 EP02768436A EP02768436A EP1420747A4 EP 1420747 A4 EP1420747 A4 EP 1420747A4 EP 02768436 A EP02768436 A EP 02768436A EP 02768436 A EP02768436 A EP 02768436A EP 1420747 A4 EP1420747 A4 EP 1420747A4
Authority
EP
European Patent Office
Prior art keywords
benzoquinone ansamycins
ansamycins
benzoquinone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02768436A
Other languages
German (de)
English (en)
Other versions
EP1420747A2 (fr
Inventor
Daniel Santi
David C Myles
Zong-Qiang Tian
C Richard Hutchinson
Robert Johnson
Yi-Qing Zhou
Li Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of EP1420747A2 publication Critical patent/EP1420747A2/fr
Publication of EP1420747A4 publication Critical patent/EP1420747A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02768436A 2001-08-06 2002-08-05 Ansamycine benzoquinone Withdrawn EP1420747A4 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US31007901P 2001-08-06 2001-08-06
US310079P 2001-08-06
US38925502P 2002-06-14 2002-06-14
US389255P 2002-06-14
US39392902P 2002-07-03 2002-07-03
US393929P 2002-07-03
US39527502P 2002-07-12 2002-07-12
US395275P 2002-07-12
PCT/US2002/024891 WO2003013430A2 (fr) 2001-08-06 2002-08-05 Ansamycine benzoquinone

Publications (2)

Publication Number Publication Date
EP1420747A2 EP1420747A2 (fr) 2004-05-26
EP1420747A4 true EP1420747A4 (fr) 2010-06-02

Family

ID=31982570

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02768436A Withdrawn EP1420747A4 (fr) 2001-08-06 2002-08-05 Ansamycine benzoquinone

Country Status (3)

Country Link
EP (1) EP1420747A4 (fr)
AU (1) AU2002330998A1 (fr)
WO (1) WO2003013430A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189549B2 (en) * 2002-06-14 2007-03-13 Kosan Biosciences, Inc. Recombinant polynucleotides encoding pro-geldanamycin producing polyketide synthase and accessory proteins, and uses thereof
RU2005133199A (ru) * 2003-03-28 2006-02-10 Козан Байосайенсиз, Инк. (Us) Устройства, способы и композиции для предупреждения рестеноза
US20050020534A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US6870049B1 (en) 2003-11-12 2005-03-22 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6855705B1 (en) 2003-11-12 2005-02-15 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6887993B1 (en) 2003-11-12 2005-05-03 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
US6875863B1 (en) 2003-11-12 2005-04-05 Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds
AU2004309395C1 (en) 2003-12-23 2012-10-04 Infinity Discovery, Inc. Analogs of benzoquinone-containing ansamycins for the treatment of cancer
US20060019941A1 (en) * 2003-12-23 2006-01-26 Infinity Pharmaceuticals, Inc. Analogs of benzoquinone-containing ansamycins and methods of use thereof
US7259156B2 (en) * 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
EP1817295B1 (fr) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Composes triazole modulant l'activite de hsp90
US7776849B2 (en) * 2005-06-29 2010-08-17 Kyowa Hakko Kirin Co., Ltd. Benzenoid ansamycin derivative
JP5118039B2 (ja) 2005-08-18 2013-01-16 シンタ ファーマシューティカルズ コーポレーション Ｈｓｐ９０活性を調節するトリアゾール化合物
EP2001455A2 (fr) 2006-03-15 2008-12-17 Theralogics, Inc. Méthodes de traitement des maladies d'atrophie musculaire au moyen d'inhibiteurs de l'activation de nf-kb
US20110091452A1 (en) * 2006-03-31 2011-04-21 Christine Martin 4,5-Dihydromacbecin Derivatives and Their Use in the Treatment of Cancer or B-Cell Malignancies
GB0606542D0 (en) * 2006-03-31 2006-05-10 Biotica Tech Ltd Novel compounds and methods for their production
WO2008044041A1 (fr) 2006-10-12 2008-04-17 Astex Therapeutics Limited Combinaisons pharmaceutiques
EP2073807A1 (fr) 2006-10-12 2009-07-01 Astex Therapeutics Limited Combinaisons pharmaceutiques
PE20081506A1 (es) 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
JP2011501731A (ja) 2007-09-10 2011-01-13 ユニバーシティ オブ マサチューセッツ ミトコンドリア標的化抗腫瘍剤
CN101220068B (zh) * 2008-01-18 2012-06-13 中国医学科学院医药生物技术研究所 一组格尔德霉素衍生物及其制备方法
ES2347619B1 (es) * 2008-05-13 2011-09-15 Consejo Superior De Investigaciones Cientificas (Csic) (50%) Procedimiento para diseñar una terapia individual antitumoral basado en la deteccion de los niveles de proteina hsp90, el uso de inhibidores de la proteina hsp90 para la elaboracion de composiciones farmaceuticas, las composiciones asi obtenidas y sus aplicaciones.
KR20110090925A (ko) 2008-10-15 2011-08-10 인피니티 파마슈티컬스, 인코포레이티드 안사마이신 하이드로퀴논 조성물
EP2560640A1 (fr) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Thérapie anticancéreuse à l'aide d'une combinaison d'un composé inhibiteur de hsp90 et d'un inhibiteur d'egfr
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
CA2853799A1 (fr) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Therapie anticancereuse utilisant une combinaison d'inhibiteurs de hsp 90 et d'inhibiteurs de topoisomerase i
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
CN112679374A (zh) * 2021-01-12 2021-04-20 湖南复瑞生物医药技术有限责任公司 2-氟-6-(三氟甲基)苯甲酰胺的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111419A (en) * 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
WO1995001342A1 (fr) * 1993-06-29 1995-01-12 Pfizer Inc. Derives de l'ansamycine utilises comme agents anti-oncogenes et anticancereux

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
JPS55111419A (en) * 1979-02-20 1980-08-28 Kaken Pharmaceut Co Ltd Antitumorigenic agent
WO1995001342A1 (fr) * 1993-06-29 1995-01-12 Pfizer Inc. Derives de l'ansamycine utilises comme agents anti-oncogenes et anticancereux

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1981, XP002577770, retrieved from STN Database accession no. 1981:71490 *
Z. LIAO E T AL, ACTA PHARMACEUTICA SINICA, vol. 36, no. 8, August 2001 (2001-08-01), pages 569 - 575, XP008045475 *

Also Published As

Publication number Publication date
WO2003013430A2 (fr) 2003-02-20
WO2003013430A3 (fr) 2004-03-04
AU2002330998A1 (en) 2003-02-24
EP1420747A2 (fr) 2004-05-26

Similar Documents

Publication Publication Date Title
EP1420747A4 (fr) Ansamycine benzoquinone
DE60213216D1 (en) Metalloproteinaseinhibitoren
DE60217478D1 (en) Sychrongleichrichter
DE60231477D1 (en) Imidazolderivate
DE60218514D1 (en) Polyolefin-kunststoffrohre
DE60234996D1 (en) Photovervielfacher
GB0105113D0 (en) Punchbag
AU2002313943A8 (en) Electromobile
GB0105568D0 (en) Bike-secure
GB0108861D0 (en) Matchit
AU2001100134A4 (en) Enviro-trap
GB0125051D0 (en) GT speedlock
PL112794U1 (en) Section
CA93127S (en) Tilt-latch
CA93125S (en) Tilt-latch
GB0126335D0 (en) Letters
AU143674S (en) An aquafoil
PL112801U1 (en) Section
PL112802U1 (en) Section
PL112803U1 (en) Section
PL112800U1 (en) Section
PL112804U1 (en) Section
AU146628S (en) Section
AU149609S (en) Section
AU146768S (en) Section

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040223

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/395 20060101ALI20100420BHEP

Ipc: C07D 491/08 20060101ALI20100420BHEP

Ipc: C07D 225/06 20060101AFI20100420BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100506

17Q First examination report despatched

Effective date: 20101228

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150703